Modern challenges in colorectal cancer

Surgeon

Volumn 4, Issue 5, 2006, Pages 285-291

  Steele, R J C ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Adjuvant therapy; Colorectal cancer; Gene mutations; Mesorectal excision; MR1; Screening

Indexed keywords

ACETYLSALICYLIC ACID; APC PROTEIN; BEVACIZUMAB; CAPECITABINE; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MISMATCH REPAIR PROTEIN PMS2; MYC PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PROTEIN MDM2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P16; PROTEIN P53; PROTEIN TYROSINE KINASE; SMAD2 PROTEIN;

ALCOHOL CONSUMPTION; BARIUM ENEMA; BRAIN HEMORRHAGE; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER SURVIVAL; CARCINOGENESIS; CIGARETTE SMOKING; COLON POLYP; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL SURGERY; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DEVELOPED COUNTRY; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; EXERCISE; FOOD INTAKE; GASTROINTESTINAL DISEASE; GENE MUTATION; HUMAN; IMMOBILIZATION; INDIVIDUALIZATION; LAPAROSCOPIC SURGERY; LIFESTYLE; LIVER METASTASIS; LIVER RESECTION; LYMPH NODE METASTASIS; MEAT; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT BLOOD TEST; PATIENT CARE; POLYPECTOMY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE RADIOTHERAPY; QUALITY OF LIFE; RECTUM ABDOMINOPERINEAL RESECTION; REVIEW; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 33749023330     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1479-666X(06)80005-3     Document Type: Review

References (61)

1. ISD Scotland. Key health topics. Cancer. Facts and figures. Colorectal (or large bowel) cancer. [cited 22 May 2002]. Available from url: http://wwwshow.scot.nhs.uk/isd/cancer/facts_figures/typescolorectal.htm
2. ISD Scotland. Cancer incidence and mortality by site/type of cancer, sex and years of diagnosis/registration of death: 1989-1998. Edinburgh: ISD Scotland: 2000. [cited 22 May 2002]. Available from url:http://www.show.scot.nhs.uk/isd/cancer/pdf/incidence_mortality/pdf
3. Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenomacarcinoma sequence. Br J Surg 2002; 89:845-60.
4. Varesco L. Familial adenomatous polyposis: genetics and epidemiology. Tech Coloproctol 2004: 8 Supple 2: s305-8.
5. Hanson CA, Miller JR. Non-traditional roles for the Adenomatous Polyposis Coli (APC) tumor suppressor protein. Gene 2005; 361: 1-12. Epub 2005 Sept 26.
6. Willert K, Jones KA. Wnt signalling: is the party in the nucleus? Genes Dev 2006; 20: 1394-404.
7. Moon A. Differential functions of Ras for malignant phenotypic conversion. Arch Pharm Res 2006; 29: 113-22.
8. Steele RJ, Lane DP. P53 in cancer: a paradigm for modem management of cancer. Surgeon 2005; 3: 197-205.
9. Leslie A, Stewart A, Baty DU, Mechan D, McGreavey L, Smith G, et al. Chromosomal changes in colorectal adenomas: relationship to gene mutations and potential for clinical utility. Genes Chromosomes Cancer 2006; 45: 126-35.
10. Lane D. Curing Cancer with p53. N Engl J Med 2004; 350: 2711-12.
11. Steele RJ, Thompson AM, Hall PA, Lane DP. The p53 tumour suppressor gene. Br J Surg 1998; 85: 1460-67,
12. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, et al. Mutations in APC, Kirsten-ras, and p53- alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 2002; 99: 9433-38.
13. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of K-ras, p53 and APC mutations in colorectal carcinoma. Gut 2005; 54: 1283-86. Epub 2005 Apr 20.
14. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005; 92:434-44.
15. Rhodes M, Bradburn DM. Overview of screening and management of familial adenomatous polyposis. Gut 1992;33: 125-31.
16. Wijnen JT, Vasen HF, Khan PM, Zwindeman AH, van der Klift H, Mulder A, et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 1998; 339:511-18.
17. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34:424-25.
18. Syngal S, Fox EA, Eng C, Kolodner RD, Garbert JE. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000;37:641-45.
19. Stubbins MJ, Wolf CR. Chapter 21. Additional polymorphisms and cancer. IARC Sci Publ 1999; (148): 271-302.
20. Michels KB, Giovannucci E, Joshipura KJ, Rosner BA, Stampfer MJ, Fuchs CS, et al. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers, J Natl Cancer Inst 2000; 92: 1740-52.
21. Norat T, Lukanova A, Ferrari P, Riboli E. Meat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies. Int J Cancer 2002; 98: 241-56.
22. Kim YI. AGA technical review: impact of dietary fiber on colon cancer occurrence, Gastroenterology 2000; 118: 1235-57.
23. Bingham SA, Day NE, Luben R, Ferrari P, Slimani N, Norat T, et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): An observational study. Lancet 2003; 361: 1496-501.
24. Corrao G, Bagnardi V, Zambon A, Arico S. Exploring the dose-response relationship between alcohol consumption and the risk of several alcohol-related conditions: a meta-analysis. Addiction 1999; 94: 1551-73.
25. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 725-31.
26. IARC Working Group on the Evaluation of Cancer Preventive Agents. Weight control and physical activity. Lyon: International Agency for Research on Cancer, 2002.
27. IARC Working Group on the Evaluation of Cancer Preventive Agents. Non-steroidal anti-inflammatory drugs. Lyon: International Agency for Research on Cancer, 1997.
28. Towler B, Inwig L, Glasziou P, Kewente J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 1998; 317: 559-65.
29. Steele RJ, Parker R, Patnick J, Warner J, Fraser C, Mowat NA, et al. A demonstration pilot trial for colorectal cancer screening in the United Kingtom: a new concept in the introduction of healthcare strategies. J Med Screen 2001; 8: 197-202.
30. UK Colorectal. Cancer Screening Pilot Group. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. BMJ 2004; 329: 133, Epub 2004 Jul 5.
31. UK Flexible Sigmoidoscopy Screening Trial Investigators. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002; 359: 1291-300.
32. Steele RJ, Gnauck R, Hrcka R, Kronborg O, Kuntz C, Moayyedi P, et al. Methods and Economic Considerations: Group I Report. ESGE/UEGF Colorectal Cancer - Public Awareness Campaign. The Public/Professional Interface Workshop: Oslo, Norway, June 20 - 22, 2003. fulfillment corporate. Endoscopy 2004; 36: 349-53.
33. Imperiale T, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351: 2704-14.
34. Thompson MR, Steele RJ, Atkin WS. Effective screening for bowel cancer: a United Kingdom perspective. Dis Colon Rectum 2006; 49: 895-908.
35. Janssens JF. Faecal occult blood test as a screening test for colorectal cancer. Acta Gastroenterol Belg 2005; 68: 244-46.
36. Fraser CG, Matthew CM, Mowat NA, Wilson JA, Carey FA, Steele RJ. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. Lancet Oncol 2006; 7: 127-31.
37. Jensen J, Kewenter J, Asztely M, Lycke G, Wojciechowski J. Double contrast barium enema and flexible rectosigmoidoscopy: a relieable diagnostic combination for detection of colorectal neoplasm. Br J Surg 1990; 77: 270-72.
38. Winawer SJ, Stewart ET, Zauber AG, Bond JH, Ansel H, Waye JD, et al. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. N Engl J Med 2000; 342: 1766-72.
39. Halligan S, Altman DG, Taylor SA, Mallett S, Deeks JJ, Bartram CI, Atkin W. CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting. Radiology 2005; 237: 893-904.
40. Scottish Intercollegiate Guidelines Network (SIGN). Guideline 67 Management of Colorectal Cancer. SIGN 2003;p 17.
41. Beets-Tan RG, Beets GL, Vliegen RF, Kessels AG, Van Boven H, De Bruine A, et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 2001; 357: 497-504.
42. Schaffzin DM, Wong WD. Endorectal ultrasound in the preoperative evaluation of rectal cancer. Clin Colorectal Cancer 2004; 4: 124-32.
43. Furukawa H, Ikuma H, Seki A, Yokoe K, Yuen S, Aramaki T, Yamaguchi S. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. Gut 2006; 55: 1007-1011.
44. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994; 344: 707-11.
45. Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998; 133: 894-99.
46. Marr R, Birbeck K, Garvican J, Macklin CP, Tiffin NJ, Parsons WJ, et al. The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg 2005; 242: 74-82.
47. Eriksen MT, Wibe A, Syse A, Haffner J, Wiig JN; Norwegian Rectal Cancer Group; Norwegian Gastrointestinal Cancer Group. Inadvertent perforation during rectal cancer resection in Norway. Br J Surg 2004; 91: 210-16.
48. Weiss EG, Wexner SD. Laparoscopic port site recurrences in oncologic surgery - a review. Ann Acad Med Singapore 1996; 25: 694-98.
49. Stocchi L, Nelson H. Minimally invasive surgery for colorectal carcinoma. Ann Surg Oncol 2005; 12: 960-70. Epub 2005.
50. Lacy AM, Garcia-Valdecasas JC, Delgado S, Castells A, Taura P, Pique JM et al. Laparoscopy assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 2002: 359: 2224-29.
51. Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, Heath RM, Brown JM; MRC CLASICC trial group. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 2005; 365: 1718-26.
52. King PM, Blazeby JM, Ewings P, Franks PJ, Longman RJ, Kendrick AH, et al. Randomized clinical trial comparing laparoscopic and open surgery for colorectal cancer within an enhanced recovery programme. Br J Surg 2006; 93: 300-8.
53. Munro AJ, Bentley AHM. Adjuvant radiotherapy in operable rectal cancer: a systematic review, Semin Colon Rectal Surg 2002; 13: 31-42.
54. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 200l; 345: 638-46.
55. Sebag-Montefiori D. Personal communication.
56. Efficacy of adjuvant fluorouracil. and folinic acid in colon cancer. International Multicentre Pooled analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345: 939-44.
57. Hoff PM, Ansari R, Batist G, Cox J, Kocba W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-92.
58. Scheele J, Stand R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19: 59-71.
59. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8: 347-53.
60. Seifert JK, Junginger T, Morris DL. A collective review of the world literature on hepatic cryotherapy. J R Coll Surg Edinb 1998; 43: 141-54.
61. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-14.